Freund's Adjuvant and Breast Cancer in Rats
Author Information
Author(s): Michelle S Cotroneo, Jill D Haag, Nicholas R Stapel, Jordy L Waller, Stephan Woditschka, Michael N Gould
Primary Institution: McArdle Laboratory for Cancer Research, University of Wisconsin-Madison
Hypothesis
Does systemic inflammation induced by Freund's adjuvant promote mammary carcinogenesis in a rat model?
Conclusion
Systemic inflammation induced by Freund's adjuvant promotes mammary carcinogenesis in rats.
Supporting Evidence
- Rats receiving Freund's adjuvant developed twice the number of mammary carcinomas as controls.
- Systemic inflammation was chronic, indicated by elevated serum haptoglobin levels.
- Increased growth of hyperplastic mammary lesions was associated with higher cell proliferation rates.
Takeaway
This study found that a substance used in vaccines can cause inflammation that might lead to breast cancer in rats.
Methodology
Rats were treated with Freund's adjuvant and monitored for mammary carcinoma development and inflammation markers.
Potential Biases
Potential bias in animal model applicability to human breast cancer.
Limitations
The study was conducted in rats, and results may not directly translate to humans.
Participant Demographics
Virgin Wistar-Furth female rats.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website